Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
02:21pm, Friday, 08'th May 2026
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 08'th May 2026
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
09:12am, Wednesday, 06'th May 2026
Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 p
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
08:30am, Wednesday, 06'th May 2026
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securiti
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
09:21am, Tuesday, 05'th May 2026
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
08:30pm, Monday, 04'th May 2026
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
04:30pm, Monday, 04'th May 2026
ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
05:10am, Thursday, 30'th Apr 2026
The biotech's candidate may treat a great number of illnesses that have one thing in common.
3 Growth Stocks That Could Generate 10X Returns
11:00am, Wednesday, 29'th Apr 2026
These stocks come with risk, but they also have some exciting long-term growth opportunities.
GSK (GSK) Tops Q1 Earnings and Revenue Estimates
08:10am, Wednesday, 29'th Apr 2026
GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today
07:01pm, Tuesday, 28'th Apr 2026
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
01:36pm, Tuesday, 28'th Apr 2026
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:09am, Tuesday, 28'th Apr 2026
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
09:06am, Monday, 27'th Apr 2026
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
3 Biotech Stocks That Could Benefit from the Patent Cliff
07:06am, Monday, 27'th Apr 2026
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
